Search Cancer Clinical Trials

Clinical Trials

Title	Veliparib and Carboplatin in Treating Women With HER2-Negative Metastatic Breast Cancer
Disease/Condition	Breast Metastatic - Chemotherapy
Description	The purpose of this trial is to study the side effects and best dose of veliparib when given with carboplatin and to see how well they work in treating women with HER2-negative metastatic breast cancer. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Veliparib may help carboplatin work better by making tumor cells more sensitive to the drug.
Eligibility Criteria	To be eligible for this study, patients must meet several criteria, including but not limited to the following: * Patient must be 18 Years and older Patient must have histologically or cytologically proven metastatic or locally advanced inoperable breast cancer that fulfills one of the following three criteria: -Triple-negative breast cancer -ER and/or PR positive, HER2 negative if their tumors have been -shown to be deficient for the FA pathway, based on FATSI immunofluorescence screening. Patient is able to swallow pills
Principal Investigator	Joseph Sparano, MD
Contact Name	Karen Fehn, RN
Phone	(718) 405-8446
Contact Email	kfehn@montefiore.org
Fax	(718) 405-8230
Post Date	12/01/2010
Protocol Number	11-03-109/West
Status	Recruiting
Current Trial Type	Interventional